Loading...
XNAS
ENTX
Market cap83mUSD
Jul 07, Last price  
1.83USD
1D
-3.17%
1Q
12.96%
IPO
-70.95%
Name

Entera Bio Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
459.54
EPS
—
Div Yield, %
—
Shrs. gr., 5y
25.39%
Rev. gr., 5y
-5.17%
Revenues
181k
000500,000236,000365,000571,000134,0000181,000
Net income
-10m
L+7.33%
-4,282,000-1,199,000-11,197,000-10,304,000-10,879,000-9,983,000-12,187,000-13,071,000-8,889,000-9,541,000
CFO
-7m
L-6.73%
-3,495,000-3,142,000-4,526,000-9,796,000-8,919,000-10,423,000-9,063,000-12,499,000-7,310,000-6,818,000
Earnings
Aug 07, 2025

Profile

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
URL
https://enterabio.com/
IPO date
Jun 28, 2018
Employees
19
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
181
 
134
-76.53%
Cost of revenue
9,766
8,996
13,202
Unusual Expense (Income)
NOPBT
(9,585)
(8,996)
(13,068)
NOPBT Margin
Operating Taxes
14
29
137
Tax Rate
NOPAT
(9,599)
(9,025)
(13,205)
Net income
(9,541)
7.33%
(8,889)
-31.99%
(13,071)
7.25%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,960
6,616
13
BB yield
-4.96%
-38.01%
-0.06%
Debt
Debt current
170
268
91
Long-term debt
374
902
91
Deferred revenue
Other long-term liabilities
32
(224)
32
Net debt
(8,116)
(9,849)
(12,127)
Cash flow
Cash from operating activities
(6,818)
(7,310)
(12,499)
CAPEX
(3)
(17)
(47)
Cash from investing activities
(3)
(17)
(102)
Cash from financing activities
4,476
6,036
13
FCF
(9,443)
(9,374)
(12,949)
Balance
Cash
8,660
11,019
12,309
Long term investments
Excess cash
8,651
11,019
12,302
Stockholders' equity
(113,885)
(104,344)
(95,456)
Invested Capital
122,269
115,286
107,333
ROIC
ROCE
EV
Common stock shares outstanding
37,650
29,008
28,808
Price
2.12
253.33%
0.60
-17.81%
0.73
-74.07%
Market cap
79,818
358.60%
17,405
-17.24%
21,030
-71.41%
EV
71,702
7,556
8,903
EBITDA
(9,539)
(8,940)
(13,004)
EV/EBITDA
Interest
26,002
Interest/NOPBT